PharmaNet/i3
, inVentiv Health’s clinical segment and a provider of clinical development services to pharmaceutical, biotechnology, generic drug and medical device companies, announced today that it is offering a mobile application in the CRO industry for bioanalytical assays. The application will provide clients the ability to search the Company’s more than 1000 bioanalytical assays from an iPhone®, iPad®, or Android™ Smartphone.
“Bioanalytical assays are used to quantitate drugs and their metabolites in a variety of matrices and are critical to the testing of new drug candidates and clinical trials,” said Farah Ahmad, Executive Director, Business Development.
“In addition to the scientific strength of our bioanalytical team and our technology platforms, this application will afford the ease of use that ourclients are seeking; it provides instant access to information from anywhere.” added Ms. Ahmad.
To access the application:
· iPad®, iPhone®:
http://itunes.apple.com/app/pharmanet-i3-bioanalytical/id577099615?mt=8
· Android™:
https://play.google.com/store/apps/details?id=com.pharmanet.Pharmanet
iPad® and iPhone® are registered trademarks of Apple Inc. Android™ is a trademark of GoogleInc.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.